1h Free Analyst Time
The pharmacogenomics market is poised to grow by $2.50 bn during 2022-2026, accelerating at a CAGR of 6.93% during the forecast period. The report on the pharmacogenomics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis of the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the rising prevalence of genetic diseases and disorders, rising approval of advanced pharmacogenomics testing products, and increasing affordability due to a reduction in the cost of genetic testing.
The pharmacogenomics market analysis includes the end-user segment and geographic landscape.
The pharmacogenomics market is segmented as below:
By End-user
- Hospitals and clinics
- Research organizations
- Academic
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the pharmacogenomics market covers the following areas:
- Pharmacogenomics market sizing
- Pharmacogenomics market forecast
- Pharmacogenomics market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market through study, synthesis, and summation of data from multiple sources by analyzing key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by End-user
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global pharmacogenomics market: 23andMe Inc., Abbott Laboratories, Admera Health, ATS GENETECH PVT. LTD., Dynamic DNA Laboratories, geneOmbio Technologies Pvt. Ltd., Illumina Inc., Laboratory Corp. of America Holdings, Mesa Labs Inc., Myriad Genetics Inc., OneOme LLC, OPKO Health Inc., QIAGEN NV, Quest Diagnostics Inc., and Thermo Fisher Scientific Inc.Commenting on the report, an analyst from the research team said: `The latest trend gaining momentum in the market is growing adoption of direct-to-consumer genetic tests in early disease diagnosis.`
According to the report, one of the major drivers for this market is the rising prevalence of genetic diseases and disorders.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 23andMe Inc.
- Abbott Laboratories
- Admera Health
- ATS GENETECH PVT. LTD.
- Dynamic DNA Laboratories
- geneOmbio Technologies Pvt. Ltd.
- Illumina Inc.
- Laboratory Corp. of America Holdings
- Mesa Labs Inc.
- Myriad Genetics Inc.
- OneOme LLC
- OPKO Health Inc.
- QIAGEN NV
- Quest Diagnostics Inc.
- Thermo Fisher Scientific Inc.
